ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

How a Chinese mRNA COVID vaccine was approved in Indonesia

Southeast Asian country aims to be more self-sufficient in dealing with pandemic

Indonesian President Joko Widodo, second right, attends the opening of Etana Biotechnologies' mRNA vaccine production site on Friday. (Photo courtesy of Etana Biotechnologies)

Indonesia will use technology from China to produce the Chinese-developed mRNA COVID-19 vaccine AWcorna in a quest to become more self-sufficient in dealing with the virus.

The Southeast Asian country's daily case tally had dropped to about 1,000 on Sunday, according to data from Johns Hopkins University. Indonesian President Joko Widodo said the rollout will allow Indonesia to "respond more calmly to COVID outbreaks in the future."

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more